Subscribe to our Email Alerts

Amplia Therapeutics Limited

Amplifying Oncology Treatments

Learn more

Amplia Therapeutics Limited

Focal Adhesion Kinase: A New Target in the Fight Against Cancer

Learn more

Amplia Therapeutics Limited

Focus on Fibrotic Cancers and Fibrosis

Learn more
 
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Company Overview

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Latest ASX Announcements

Our Technology

Innate has an exclusive worldwide licence to develop and commercialise two best-in-class FAK inhibitors (FAKi) developed by the Cancer CRC : AMP945 and AMP886

ASX Share Price

Market Cap:
Price Delay ~20min